首页> 外国专利> Regioselective preparation of alkyl 4-alkanoylamino-3-alkyl-5-nitrobenzoic acid derivatives, useful as intermediates for benzimidazole derivative drugs, by nitration of 5-unsubstituted analogs under controlled conditions

Regioselective preparation of alkyl 4-alkanoylamino-3-alkyl-5-nitrobenzoic acid derivatives, useful as intermediates for benzimidazole derivative drugs, by nitration of 5-unsubstituted analogs under controlled conditions

机译:通过在受控条件下硝化5-未取代的类似物,选择性地制备烷基4-烷酰基氨基-3-烷基-5-硝基苯甲酸衍生物,用作苯并咪唑衍生物药物的中间体

摘要

The preparation of alkyl 4-alkanoylamino-3-alkyl-5-nitrobenzoic acid derivatives (I) by nitration of 5-unsubstituted analogs (II) involves: (1) dissolving (II) in a solvent mixture of sulfuric acid (1.5-2.5 moles), nitric acid (1.5-2.5 moles) and water (2-6 moles); and (2) treating the mixture with nitric acid (6-10 moles). The preparation of alkyl 4-alkanoylamino-3-alkyl-5-nitrobenzoic acid derivatives of formula (I) by nitration of 5-unsubstituted analogs of formula (II) involves: (1) dissolving (II) in a solvent mixture of sulfuric acid (1.5-2.5 moles), nitric acid (1.5-2.5 moles) and water (2-6 moles); and (2) treating the mixture with nitric acid (6-10 moles). R1, R2 = H or 1-6C alkyl; R3 = H or (1-5C) alkylcarbonyl; R4 = H; or R3 + R4 = succinyl, glutaryl or adipyl. Independent claims are also included for: (1) 2-propyl-4-methyl-6-methoxycarbonyl-benzimidazole (IIIa), prepared by nitration of methyl 4-butyrylamino-3-methyl-benzoate (IIa) as described above, reduction of the nitro group to amino and condensing the carbonyl function of the butyryl residue with the primary amino function; and (2) 2-propyl-4-methyl-6-(N-methyl-benzimidazol-2-yl)-benzimidazole (IIIb), prepared from (IIIa) (as defined in (1)) by saponification of the methoxycarbonyl group followed by reaction with o-N-methyl-phenylene diamine.
机译:通过硝化5-未取代的类似物(II)制备烷基4-烷酰基氨基-3-烷基-5-硝基苯甲酸衍生物(I)涉及:(1)将(II)溶解在硫酸(1.5-2.5)的溶剂混合物中摩尔),硝酸(1.5-2.5摩尔)和水(2-6摩尔); (2)用硝酸(6-10摩尔)处理混合物。通过硝化式(II)的5-未取代的类似物来制备式(I)的烷基4-烷酰基氨基-3-烷基-5-硝基苯甲酸衍生物包括:(1)将(II)溶解在硫酸的溶剂混合物中(1.5-2.5摩尔),硝酸(1.5-2.5摩尔)和水(2-6摩尔); (2)用硝酸(6-10摩尔)处理混合物。 R1,R2 = H或1-6C烷基; R3 = H或(1-5C)烷基羰基; R4 = H;或者R3 + R4 =琥珀酰基,戊二酰基或己二酰基。还包括以下方面的独立权利要求:(1)2-丙基-4-甲基-6-甲氧基羰基-苯并咪唑(IIIa),其通过如上所述将4-丁酰基氨基-3-甲基-苯甲酸甲酯(IIa)硝化,硝基成氨基,使丁酰基残基的羰基官能团与伯氨基官能团缩合; (2)通过将甲氧基羰基皂化而由(IIIa)(如(1)所定义)制备的2-丙基-4-甲基-6-(N-甲基-苯并咪唑-2-基)-苯并咪唑(IIIb)然后与oN-甲基-亚苯基二胺反应。

著录项

  • 公开/公告号DE19917524A1

    专利类型

  • 公开/公告日2000-10-19

    原文格式PDF

  • 申请/专利权人 BOEHRINGER INGELHEIM PHARMA KG;

    申请/专利号DE19991017524

  • 发明设计人 SCHNEIDER HEINRICH;

    申请日1999-04-17

  • 分类号C07D235/06;C07C231/16;C07C229/60;C07C233/54;C07C227/16;C07C231/12;C07D235/20;C07B53/00;

  • 国家 DE

  • 入库时间 2022-08-22 01:42:11

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号